Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Oct;1(4):314-322.
doi: 10.4161/self.1.4.13904.

Immunogenicity of protein therapeutics: The key causes, consequences and challenges

Matthew P Baker  1 , Helen M Reynolds, Brooke Lumicisi, Christine J Bryson
Affiliations

Immunogenicity of protein therapeutics: The key causes, consequences and challenges

Matthew P Baker et al. Self Nonself. 2010 Oct.

Abstract

The immunogenicity of protein therapeutics has so far proven to be difficult to predict in patients, with many biologics inducing undesirable immune responses directed towards the therapeutic resulting in reduced efficacy, anaphylaxis and occasionally life threatening autoimmunity. The most common effect of administrating an immunogenic protein therapeutic is the development of a high affinity anti-therapeutic antibody response. Furthermore, it is clear from clinical studies that protein therapeutics derived from endogenous human proteins are capable of stimulating undesirable immune responses in patients, and as a consequence, the prediction and reduction of immunogenicity has been the focus of intense research. This review will outline the principle causes of the immunogenicity in protein therapeutics, and describe the development of pre-clinical models that can be used to aid in the prediction of the immunogenic potential of novel protein therapeutics prior to administration in man.

PubMed Disclaimer

References

    1. Bertolotto A, Malucchi S, Sala A, Orefice G, Carrieri PB, Capobianco M, et al. Differential effects of three interfeorn betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory. J Neurol Neurosurg Psychiatry. 2002;73:148–153. - PMC - PubMed
    1. Bertolotto A, Sala A, Malucchi S, Marnetto F, Caldano M, Di Sapio A, et al. Biological activity of interferon betas in patients with multiple sclerosis is affected by treatment regimen and neutralising antibodies. J Neurol Neurosurg Psychiatry. 2004;75:1294–1299. - PMC - PubMed
    1. Cook SD, Quinless JR, Jotkowitz A, Beaton P. Serum IFN neutralizing antibodies and neopterin levels in a cross-section of MS patients. Neurology. 2001;57:1080–1084. - PubMed
    1. Ryff JC. Clinical investigation of the immunogenicity of interferon-alpha2a. J Interferon Cytokine Res. 1997;17:29–33. - PubMed
    1. Von Wussow P, Hehlmann R, Hochhaus T, Jakschies D, Nolte KU, Prümmer O, et al. Roferon (rIFNalpha2a) is more immunogenic than intron A (rIFNalpha2b) in patients with chronic myelogenous leukemia. J Interferon Res. 1994;14:217–219. - PubMed

LinkOut - more resources